Sofinnova Investments related stories
All articles and analysis
Late Stage & Secondary Funds Strong Suit For San Francisco Pension Fund's Venture PortfolioAverage investment multiples are higher for later stage and secondary commitments made since 2005, compared with other funds of the same vintages, and median IRRs for the later and secondary fund investments from earlier in the decade are better as well.
- California Pension Fund's Diversified Approach To Venture Appears To Benefit Performance: Slideshow
SFERS, with $13 billion in net assets at the end of fiscal 2010 and 3.8% of its holdings in venture capital, has committed about $899 million to the asset class since the start of 2000, according to a peHUB analysis of its recent public portfolio report. That’s meant investing in 45 funds, the analysis found.
- Catalyst Biosciences Inks $7M from Phizer
Catalyst Biosciences Inc. has sealed a $7 million milestone payment from Pfizer, as part of a research and license agreement between the two companies. Catalyst recently initiated Phase 1 clinical trials for one of its products, designed to help treat hemophilia patients. Privately held Catalyst is backed by investors including Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures, RCT BioVentures and Sofinnova Ventures.
- Takeda Pharmaceutical Buys VC-Backed Intellikine
Takeda Pharmaceutical Company, a listed, Japanese pharmaceutical research company, is buying venture-backed Intellikine Inc. Takeda will pay $190 million in cash, and up to $120 million in additional milestone payments. Intellikine was backed by at least $41 million from venture investors including Abingworth, BiogenIdec, CMEA Capital, Fintech Global Capital, Novartis Venture Funds, Sofinnova Ventures and U.S. Venture Partners.
- peHUB First Read
Cowa-Bunga-Bunga: Berlusconi’s http://www.reuters.com/article/2011/11/08/us-italy-idUSTRE7A72NG20111108 outta here! L’Chaim! Sofinnova Ventures eyes http://www.globes.co.il/serveen/globes/docview.asp?did=1000695842&fid=1725 Israel Back in Action: SAC Capital spinoff Siris http://www.sfgate.com/cgi-bin/article.cgi?f=/g/a/2011/11/07/bloomberg_articlesLUB90Z6S972Q.DTL They’ll be Back: Occupy Zuccotti http://www.seattlepi.com/entertainment/article/Occupy-protesters-plan-march-from-NYC-to-DC-2258142.php protestors plot NY-to-DC march Me, Too! Now Yelp http://dealbook.nytimes.com/2011/11/08/yelp-hires-goldman-and-citigroup-to-lead-i-p-o/ wants to go public Fund Founded: Thiel's fund said to be raising up to $600 million http://www.bloomberg.com/news/2011-11-08/thiel-s-founders-fund-is-said-to-be-raising-up-to-600-million-in-capital.html Stashing the Cash: JC Flowers http://www.reuters.com/article/2011/11/09/us-jcflowers-idUSTRE7A82DU20111109 weathers global market turmoil Cloud's Silver Lining: CX.com http://techcrunch.com/2011/11/08/cloud-storage-startup-cx-hires-former-rim-cmo-rolls-out-collaboration-suite-free-storage/ start-up rolls out new product and boosts management team Bring it Back: Back9 http://www.masshightech.com/stories/2011/11/07/daily18-Back9-brings-on-Javier-Colon-new-funding.html boosts funding round A Healthy Start: Healthcare resource start-up Kyruus http://www.masshightech.com/stories/2011/11/07/daily16-Physician-resources-startup-Kyruus-raises-3M.html raises $3 million
- Intellikine Adds $4M in Milestone Payments
Biopharma company Intellikine Inc. has sealed $4 million in new milestone payments as it begins two Phase 1 clinical trials of its drugs. The company, based in La Jolla, Calif., is backed by $41 million from venture investors including Abingworth, BiogenIdec, CMEA Capital, Fintech Global Capital, Novartis Venture Funds, Sofinnova Ventures and U.S. Venture Partners.
- peHUB First Read
No IPO: Xunlei http://www.filmbiz.asia/news/xunlei-cancels-its-ipo backs away from plans to go public Uh Oh: Can't unload http://uncrunched.com/2011/10/14/secondmarket-facebook-auction-43-fails-to-clear-any-shares/ those Facebook shares now? Uh-Oh, Pt. II: WL Ross http://www.reuters.com/article/2011/10/15/us-wlrossco-idUSTRE79E0AK20111015 backing away from fundraising target? CVC's Virgin Active deal OK-ed http://www.reuters.com/article/2011/10/14/virginactive-cvc-eu-idUSL5E7L63II20111014 by EU authorities Will the Next Steve Jobs be a woman http://blogs.reuters.com/katharine-herrup/2011/10/10/will-the-next-steve-jobs-be-a-woman/ Doughnuts Do the Rounds Krispy Kreme http://www.telegraph.co.uk/finance/newsbysector/retailandconsumer/8830406/British-arm-of-Krispy-Kreme-bought-by-private-equity-firm.html UK goes for £25m
- Allergan Buys Vicept Therapeutics
Allergan is buying privately held dermatology company Vicept Therapeutics. Formed in 2009, Vicept is backed by investors including Vivo Ventures, Fidelity Biosciences and Sofinnova Ventures. Under the terms of the acquisition, which is expected to close during the third quarter, Allergan will pay $75 million in cash up-front, as well as up to $200 million in payments tied to specific milestones.
- SARcode Bioscience Inks $44M Series B
Brisbane, Calif.-based SARcode Bioscience has closed on $44 million in Series B financing, led by Sofinnova Ventures. Rho Ventures also participated, as did existing investors Alta Partners and Clarus Venture Partners. The money will go toward clinical development of the company’s treatment for dry eye syndrome.